Pexmetinib

Drug Profile

Pexmetinib

Alternative Names: ARRY 614; Pexmetinib hydrochloride

Latest Information Update: 30 Aug 2016

Price : $50

At a glance

  • Originator Array BioPharma
  • Class Anti-inflammatories; Antineoplastics; Indazoles; Pyrazoles; Small molecules; Urea compounds
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors; TIE 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Myelodysplastic syndromes
  • Discontinued Inflammation

Most Recent Events

  • 17 Oct 2014 Suspended - Phase-I for Myelodysplastic syndromes in USA (PO)
  • 09 Dec 2013 Interim efficacy and adverse events data from a phase I trial in Myelodysplastic syndromes presented at the 55th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2013)
  • 30 Sep 2013 Array BioPharma completes enrolment in a phase I trial for Myelodysplastic syndromes in USA (NCT01496495)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top